← VSEE
VSEE— VSEE HEALTH, INC.
| Metric | FY2025 | FY2024 | FY2024 | FY2024 | FY2024 | FY2023 | FY2023 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | $3K-100.0% | $10.4M+151373.1% | $7K-99.6% | $1.6M+13.1% | $1.4M | — | $1.3M-19.4% | $1.6M-52.7% | $3.3M | — |
| Cost of revenues | $7.3M+123.9% | $3.2M+469.3% | $570K-39.0% | $935K-29.2% | $1.3M | — | $1.9M-41.7% | $3.2M+67.8% | $1.9M | — |
| Gross margin | $7.4M+2.5% | $7.2M+157.8% | $2.8M+258.4% | $777K-37.1% | $1.2M-67.8% | $3.8M+301.6% | $954K+19.7% | $797K-20.5% | $1.0M | — |
| Compensation and related benefits | $6.9M+30.1% | $5.3M+206.7% | $1.7M+89.6% | $913K-49.5% | $1.8M | — | $3.5M-33.4% | $5.3M+20.1% | $4.4M | — |
| Goodwill impairment charges | $0-100.0% | $56.7M+0.0% | $56.7M+0.0% | $56.7M+0.0% | $56.7M | — | — | — | — | — |
| General and administrative | $10.0M+53.1% | $6.6M+195.5% | $2.2M+290.2% | $568K+169.7% | $211K-82.5% | $1.2M+322.2% | $285K-26.3% | $386K+13.2% | $341K | — |
| Transaction expenses | $0-100.0% | $793K+73.9% | $456K+99.7% | $228K-10.3% | $255K | — | $710K-10.4% | $793K+813.4% | $87K | — |
| Total operating expenses | $16.9M-75.6% | $69.3M+13.5% | $61.1M+3472.9% | $1.7M+51.2% | $1.1M-80.2% | $5.7M+336.5% | $1.3M-12.1% | $1.5M-13.4% | $1.7M | — |
| Net operating loss | -$9.6M+84.6% | -$62.2M-6.6% | -$58.3M-6151.3% | -$933K-996.1% | $104K+105.6% | -$1.9M-430.7% | -$353K+48.8% | -$690K+3.6% | -$716K+80.1% | -$3.6M |
| Interest expense | -$2.8M-1229.7% | -$211K-83.3% | -$115K+66.2% | -$342K+2.7% | -$351K | — | -$467K-120.6% | -$211K-10.5% | -$191K | — |
| Other income, net | $47K+9310.5% | $504+0.0% | $504+102.5% | -$20K | — | — | — | — | — | — |
| Change in fair value of financial instruments | -$1.5M-123.5% | $6.2M+0.0% | $6.2M+6747.1% | $90K | — | — | — | — | — | — |
| Gain on extinguishment of Equity Line of Credit (“ELOC”) | $42K | $0 | — | — | — | — | — | — | — | — |
| Loss on extinguishment of debt | -$221K+65.8% | -$646K+0.0% | -$646K+0.0% | -$646K+0.0% | -$646K | — | — | — | — | — |
| Loss on issuance of financial instruments | -$668K+73.4% | -$2.5M-322.4% | -$595K+73.1% | -$2.2M+11.9% | -$2.5M | — | — | — | — | — |
| Total other (expense) income, net | -$5.1M-280.4% | $2.8M-36.0% | $4.4M+410.3% | -$1.4M+0.7% | -$1.4M | — | $3.0M+5.5% | $2.8M+21078.9% | -$13K-102.5% | $540K |
| Loss before (provision for) benefit from income taxes | -$14.6M+75.3% | -$59.3M-10.1% | -$53.9M-2199.6% | -$2.3M-2574.4% | $95K+105.0% | -$1.9M-359.1% | -$411K+39.7% | -$682K+5.0% | -$718K+76.5% | -$3.1M |
| (Provision for) benefit from income taxes | -$68K-104.2% | $1.6M+18765.1% | -$9K-100.5% | $1.7M+0.0% | $1.7M | — | $1.7M+1.6% | $1.6M+189.4% | -$1.8M | — |
| Net loss | -$14.7M+74.5% | -$57.7M-7.0% | -$53.9M-7995.2% | -$666K-803.0% | $95K+102.5% | -$3.7M-2001.3% | -$177K+65.1% | -$507K+5.1% | -$535K+83.5% | -$3.2M |
| Basic loss per common share (in Dollars per share) | -$0.73+87.1% | -$5.65-57.8% | -$3.58-2883.3% | -$0.12-1300.0% | $0.01+102.6% | -$0.38-1800.0% | -$0.02+81.8% | -$0.11-120.0% | -$0.05+80.0% | -$0.25 |
| Diluted loss per common share (in Dollars per share) | -$0.73+87.1% | -$5.65-57.8% | -$3.58-35900.0% | $0.01+150.0% | -$0.02 | — | -$0.11-120.0% | -$0.05+54.5% | -$0.11+56.0% | -$0.25 |
| Weighted average number of common shares outstanding, basic (in Shares) | $20.1M+97.2% | $10.2M+0.0% | $10.2M+2.1% | $10.0M | — | — | — | — | — | $12.7M |
| Weighted average number of common shares outstanding, diluted (in Shares) | $20.1M+97.2% | $10.2M+0.0% | $10.2M+2.1% | $10.0M | — | — | — | — | — | $12.7M |
| Subscription fees | ||||||||||
| Professional services and other fees | ||||||||||
| Technical engineering fees | ||||||||||
| Patient fees | ||||||||||
| Telehealth fees | ||||||||||
| Institutional fees | ||||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.